learn Fluridil
a topical anti-androgen with less systemic involvement
Search
forLearn
5 / 801 resultslearn Epidermal Growth Factor
learn sh-Polypeptide-7
learn Pyrilutamide
highly targeted anti-androgen that might have minimal systemic effects
learn GT20029
research compound made to degrade androgen receptors in scalp
Research
5 / 1000+ resultsresearch The systemic wrinkled skin phenotype involves aberrant expression and variation of genes related to the oxidative stress and extracellular matrix in Xiang pigs
Wrinkled skin in Xiang pigs is linked to gene changes related to oxidative stress and the extracellular matrix.
research Emerging Strategies in Smart Nano-PROTAC for Stimuli-Responsive Protein Degradation and Precision Cancer Therapy
Smart nano-PROTACs improve cancer treatment by targeting proteins more precisely and reducing side effects.
research Mechanisms of autophagy and their implications in dermatological disorders
Targeting autophagy can help treat skin disorders like vitiligo and atopic dermatitis.
research Skin metabolism in obesity: A narrative review
Obesity harms skin health by causing inflammation and delayed wound healing.
research Keratins as an Inflammation Trigger Point in Epidermolysis Bullosa Simplex
Mutant keratins cause inflammation in Epidermolysis Bullosa Simplex, suggesting targeting them could help treat the disorder.
Community Join
5 / 1000+ resultscommunity Protac degradation of the androgen receptor in mice shows good efficacy and no systemic drug could be found
The efficacy of degrading the androgen receptor through dermal application in DP cells, a delivery system for topical drugs that involves dissolving microneedles, and rosemary oil as an alternative anti-androgen.
community Does pyrilutamide degrade to an inactive form if it goes systemic like fluridil
Pyrilutamide's systemic degradation is unclear, unlike fluridil, which becomes inactive in the body. The discussion focuses on whether pyrilutamide shares this property.
community GT-20029 should be much more superior than finasteride
GT-20029 is discussed as a potential hair loss treatment, with concerns about its safety and systemic absorption compared to finasteride. Users express skepticism about its effectiveness and safety, noting that it may not surpass existing treatments like finasteride and minoxidil.
community A concern regarding the upcoming androgen degrader drug GT20029
GT20029 is a topical treatment that degrades androgen receptors to prevent hair thinning and loss, potentially offering fewer side effects than systemic treatments like finasteride. Concerns include its impact on hair texture and potential systemic effects, with market availability speculated in 3 to 5 years.
community AH-001 another topical AR degrader beside GT20029, completed Phase I
AH-001 is a new topical treatment designed to degrade androgen receptors, targeting the root cause of androgenetic alopecia without the side effects of oral treatments like finasteride. It has shown a strong safety profile and good local tolerability in early trials.